Following on from information provided to NICE by the company in June 2019, the appraisal of Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1503 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 26 June 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual